To evaluate the effectiveness of baroreflex activation therapy (BAT) in managing symptoms and quality of life in patients with transthyretin amyloid cardiomyopathy (TTR-CM) and refractory heart failure.
Administered baroreflex activation therapy to selected patients with TTR-CM
Monitored symptoms and quality of life improvements over time
Patients experienced significant improvement in symptoms
Quality of life metrics showed positive changes
Abstract
BAT may be a useful adjunctive therapy to improve symptoms and quality of life in selected patients with TTR-CM and refractory heart failure.